Jessica Walters

Centanafadine demonstrates promising effects on ADHD symptoms, enhancing key neurotransmitters without increasing psychomotor activity, according to poster data.

A look at upcoming presentations at APSARD 2026, January 15-18.

NTX-253 enters phase 1 trials, exploring a novel approach to schizophrenia treatment with potential for improved safety and efficacy.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.

Clinicians can guide patients with bipolar disorder in setting flexible, achievable New Year’s goals, enhancing motivation and stability throughout mood fluctuations.

Discover groundbreaking findings on digital therapeutics and medications for schizophrenia and depression, showcasing safety and efficacy in recent studies.

Explore innovative treatments for schizophrenia, depression, and dementia, focusing on new medications and holistic care approaches for better patient outcomes.

Explore innovative approaches to mental health care, from jail diversion programs to addressing burnout in female physicians, enhancing patient outcomes.

Review the news from this year's Clinical Trials in Alzheimer's Disease conference.

See the variety of commentary, news, and happenings in artificial intelligence (AI) and psychiatry throughout this year.

See the latest developments in narcolepsy research.

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

Cobenfy gains NMPA approval in China, offering a groundbreaking treatment for schizophrenia with a unique mechanism and improved symptom management.

Vistagen's fasedienol fails to show significant efficacy in treating social anxiety disorder, despite favorable safety data from the PALISADE-3 trial.

Discover new research on schizophrenia treatments, including digital therapeutics and valbenazine, showcasing significant improvements in patient outcomes.

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.

A groundbreaking at-home brain stimulation device gains FDA approval, offering hope for adults with major depressive disorder through innovative treatment.

New research suggests semaglutide may protect against lithium-induced renal injury, offering hope for safer bipolar disorder treatments.

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

A recent survey reveals that 13% of US youth use generative AI for mental health advice, highlighting its perceived benefits and potential risks.

New neuroimaging data reveals XPro1595's potential to combat neuroinflammation in early Alzheimer’s disease, offering hope for slowing progression.

Explore updates from November 2025, including AI, drug updates, and more.

Tiffani Bell-Washington, MD, MPH shares insights on compassionate lifestyle changes for adolescents facing obesity, emphasizing collaboration and individualized care strategies.

Otsuka Pharmaceutical submits a new drug application for centanafadine for treatment of ADHD, showing significant efficacy across all age groups.

Hormonal fluctuations significantly influence ADHD symptoms in women, highlighting the need for tailored treatments and further research in this area.

Experts discuss the advantages of long-acting injectables in schizophrenia treatment, highlighting improved adherence, reduced relapse risk, and better patient outcomes.